FI930719A - Farmaceutiska foereningar - Google Patents

Farmaceutiska foereningar Download PDF

Info

Publication number
FI930719A
FI930719A FI930719A FI930719A FI930719A FI 930719 A FI930719 A FI 930719A FI 930719 A FI930719 A FI 930719A FI 930719 A FI930719 A FI 930719A FI 930719 A FI930719 A FI 930719A
Authority
FI
Finland
Prior art keywords
alkyl
optionally substituted
hydrogen
phenyl
cor
Prior art date
Application number
FI930719A
Other languages
English (en)
Finnish (fi)
Other versions
FI930719A0 (fi
Inventor
Michael Brunavs
Colin Peter Dell
Peter Thaddeus Gallagher
William Martin Owton
Colin William Smith
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI930719A0 publication Critical patent/FI930719A0/fi
Publication of FI930719A publication Critical patent/FI930719A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI930719A 1992-02-19 1993-02-18 Farmaceutiska foereningar FI930719A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929203497A GB9203497D0 (en) 1992-02-19 1992-02-19 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
FI930719A0 FI930719A0 (fi) 1993-02-18
FI930719A true FI930719A (fi) 1993-08-20

Family

ID=10710655

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930719A FI930719A (fi) 1992-02-19 1993-02-18 Farmaceutiska foereningar

Country Status (23)

Country Link
US (3) US5378699A (ja)
EP (1) EP0557075B1 (ja)
JP (1) JPH061784A (ja)
KR (1) KR100274103B1 (ja)
CN (1) CN1038680C (ja)
AT (1) ATE167675T1 (ja)
AU (1) AU664412B2 (ja)
CA (1) CA2089974A1 (ja)
CZ (1) CZ21793A3 (ja)
DE (1) DE69319262T2 (ja)
DK (1) DK0557075T3 (ja)
ES (1) ES2117097T3 (ja)
FI (1) FI930719A (ja)
GB (1) GB9203497D0 (ja)
HU (1) HUT63844A (ja)
IL (1) IL104739A (ja)
MX (1) MX9300840A (ja)
MY (1) MY109777A (ja)
NO (1) NO301712B1 (ja)
NZ (1) NZ245906A (ja)
RU (1) RU2083572C1 (ja)
TW (1) TW257760B (ja)
ZA (1) ZA931097B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
US5925673A (en) * 1994-12-23 1999-07-20 Alcon Laboratories, Inc. Benzofurans and benzopyrans as cytoprotective agents
US5811453A (en) 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Viscoelastic compositions and methods of use
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
FR2796312B1 (fr) * 1999-07-16 2001-09-07 Atofina Catalyseur metallique supporte, sa preparation et ses applications dans la fabrication directe du peroxyde d'hydrogene
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
DE102004032418A1 (de) * 2004-04-07 2005-10-27 Bayer Cropscience Ag Wirkstoffkombinationen mit insektiziden Eigenschaften
US10730885B1 (en) 2019-04-30 2020-08-04 King Saud University Coumarin derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243674A (en) * 1978-06-12 1981-01-06 Pfizer Inc. 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore
US4931221A (en) * 1988-12-30 1990-06-05 Ppg Industries, Inc. Photochromic spiropyran compounds
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5281619A (en) * 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications

Also Published As

Publication number Publication date
CN1076696A (zh) 1993-09-29
CZ21793A3 (en) 1994-02-16
ATE167675T1 (de) 1998-07-15
MY109777A (en) 1997-06-30
HUT63844A (en) 1993-10-28
IL104739A0 (en) 1993-06-10
MX9300840A (es) 1993-09-01
EP0557075B1 (en) 1998-06-24
NO301712B1 (no) 1997-12-01
DK0557075T3 (da) 1998-12-14
DE69319262T2 (de) 1998-11-12
ZA931097B (en) 1994-08-17
HU9300446D0 (en) 1993-05-28
IL104739A (en) 1997-01-10
CA2089974A1 (en) 1993-08-20
US5663375A (en) 1997-09-02
NO930559L (no) 1993-08-20
TW257760B (ja) 1995-09-21
AU3309993A (en) 1993-08-26
JPH061784A (ja) 1994-01-11
RU2083572C1 (ru) 1997-07-10
NO930559D0 (no) 1993-02-17
AU664412B2 (en) 1995-11-16
KR100274103B1 (ko) 2000-12-15
DE69319262D1 (de) 1998-07-30
GB9203497D0 (en) 1992-04-08
ES2117097T3 (es) 1998-08-01
US5378699A (en) 1995-01-03
KR930017887A (ko) 1993-09-20
FI930719A0 (fi) 1993-02-18
CN1038680C (zh) 1998-06-10
NZ245906A (en) 1995-04-27
US5622987A (en) 1997-04-22
EP0557075A1 (en) 1993-08-25

Similar Documents

Publication Publication Date Title
FI941396A0 (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
DK0539204T3 (da) Antivirale 4-substituerede-deoxy-2,3-didehydroderivater af alfa-D-neuraminsyre
DE69604714T2 (de) Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
BR0214277A (pt) Solvatos de paclitaxel
FI930719A0 (fi) Farmaceutiska foereningar
DK98088D0 (da) Farmaceutisk formulering med forsinket frigivelse af den aktive bestanddel
DK0506613T3 (da) Smøremiddelholdige vandige præparater af copolymerer
HUT62281A (en) Process for producing new naphto/1,2-b/pyran derivatives and pharmaceutical compositions comprising same as active ingredient
DE60023647D1 (de) Makrolide mit entzündungshemmender wirkung
BR9107159A (pt) Composicoes de sulfonamidas herbicidas protegidas
FI851261L (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DE69825977D1 (de) Antivirale mittel
RU93004522A (ru) Дигидронафтопирановые соединения, способ их получения и фармацевтическая композиция
ITMI932189A0 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
DE69111530D1 (de) Pyridincarbonsäure-Amid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
FR2670785B1 (fr) Derives de (methoxy-4 phenyl)-2 (methylamino-2 ethyl)-5 dihydro-2,3 5h-benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique.
DK0779075T3 (da) Anvendelse af 3-alpha-hydroxy-5-alpha-androsta-16-en som lægemidler
BR7002132U (pt) Base de medicao
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
ITMI921253A0 (it) Composizione farmaceutica avente attivita' antivirale
SU1602007A1 (ru) 6-(4,5-Дифенилтиенил-2)-3-тиа-1,2,4-триазин-5-он, проявляющий противовоспалительную и антимикробную активность